Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC.  Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters:Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d’Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.